Brivaracetam exposure-response predictions in pediatric patients from age 1 month: Extrapolation of levetiracetam adult-pediatric scaling to brivaracetam

• DOI: 10.1016/j.eplepsyres.2024.107332
• Publication Date: 2024-02-21T16:33:27Z
• Authors: Rik Schoemaker; Walter Krauwinkel; Jan-Peer Elshoff; Armel Stockis
• Keywords: Levetiracetam

An adult population pharmacokinetic/pharmacodynamic (PK/PD) model for the antiseizure medication (ASM) brivaracetam (BRV) was previously extended to children aged 4-16 years by using a pediatric BRV PK model. Effects were scaled information from combined adult-pediatric PK/PD of related ASM, levetiracetam (LEV).